Mexican digital pharmacy startup Prixz closed 2025 with triple-digit growth, expanded national coverage and a sharpened focus on chronic disease management, positioning the company for further scale as online health transactions gain share in Mexico’s US$24 billion private healthcare market.
At a Feb. 10 press conference, Prixz co-founder and digital director Sergio “Checo” Pérez said the company ended 2025 with cumulative growth of 300% since 2022, more than 7 million site visits and a catalog of approximately 15,000 medications — roughly five times the assortment typically stocked by a brick-and-mortar pharmacy. Prixz now dispatches more than 10,000 orders per day and reaches 98.7% of Mexico’s territory, making it the digital pharmacy with the broadest national coverage.
Founded in 2020 as a fully digital operation with no physical storefronts, Prixz said it was valued at more than US$100 million in its most recent funding round, backed by Mexican and Silicon Valley investors. The company holds about 4% of Mexico’s digital pharmacy market and ranks as the third-largest pharmacy platform by online traffic, according to external audience measurement firms.
Prixz operates within a healthcare market undergoing structural transformation. Industry estimates presented at the press conference project that Mexico’s private healthcare market will exceed US$24 billion in 2026, with digital channels accounting for approximately 16% of total sales. By 2028, analysts expect digital transactions to represent up to 30% of private pharmaceutical sales in Mexico and across Latin America, following adoption patterns previously observed in parts of Europe.
While overall pharmaceutical sales in Mexico are expanding at roughly 1% annually, Pérez said digital health transactions are growing at a significantly faster rate, driven by convenience, broader product availability and evolving consumer behavior. Prixz was founded to address persistent access and efficiency gaps in traditional pharmacy models, particularly for patients managing chronic illnesses.
Company data indicate that patients in Mexico must visit an average of 2.9 physical pharmacies to complete a prescription, largely because a typical retail pharmacy stocks around 3,000 medications, compared with the 15,000 to 18,000 available nationally. Access challenges are more acute outside major metropolitan areas, where limited inventory and longer travel distances extend fulfillment times. Surveys cited by Prixz show that patients spend an average of 70 minutes filling a prescription through traditional channels, including travel and in-store waiting.
Pérez linked these inefficiencies to treatment abandonment in a country with a high prevalence of chronic disease. According to national health data referenced at the event, 18.3% of Mexico’s adult population lives with diabetes, nearly one-third has hypertension, and significant segments manage long-term conditions such as hypercholesterolemia, thyroid disorders, depression and obesity.
Prixz: Integrating Last-Mile Delivery Into the Mexican Pharmaceutical Ecosystem
Prixz’s model centers on delivering complete prescriptions through a single digital platform with home or workplace delivery. Orders can be placed in minutes, with same-day or near-immediate delivery in major urban centers. The company operates a network of last-mile fulfillment hubs — known internally as “CRUMS” — which function as closed-to-the-public pharmacies dedicated exclusively to rapid dispatch. Between late 2025 and February 2026, Prixz added six new CRUMS, expanding delivery-in-minutes service across Mexico City, Guadalajara and the State of Mexico, while broadening reach to cities including Veracruz, Puebla and Mérida. In other regions, deliveries are typically completed within 12 hours.
Operational metrics presented at the event suggest stronger engagement than traditional pharmacy channels. Prixz’s average ticket size is three to four times higher than that of a street-level pharmacy, reflecting an average basket of three products per order and the fulfillment of full treatment regimens. Approximately 22% of customers made repeat purchases within the past 12 months, with refills most commonly reordered within a 28- to 35-day window, closely aligned with chronic treatment cycles.
Pérez highlighted 2025 purchasing data as evidence of evolving health priorities. Top-selling medications included treatments for diabetes, cholesterol and metabolic conditions—such as semaglutide, atorvastatin, insulin and glucagon—as well as mental health therapies including sertraline and attention deficit medications. Preventive and wellness products, including creatine, probiotics, collagen and keratin supplements, also ranked among the most purchased items, reflecting rising consumer spending on prevention, fitness and quality-of-life improvements.
Over the past three years, demand patterns have remained consistent, led by treatments for diabetes, hypertension, cholesterol, thyroid disorders, depression, anxiety and obesity. Growth has also been recorded in dermatology, antioxidant therapies and female fertility treatments, the latter showing notable expansion over the past year.
Demographic data challenged assumptions about digital health adoption. More than 60% of Prixz users are between 35 and 65 years old, while more than 15% are over age 65. Women account for approximately 70% of purchasers, many serving as primary health managers for their households and purchasing medications for children, parents and elderly relatives. Executives said this dynamic accelerated during the pandemic and has since become structural.
Although the core user base skews toward middle- and upper-middle-income segments, Prixz reported sustained delivery to remote and underserved regions, including regular shipments to areas such as the Lacandon Jungle, where patients with chronic conditions have received uninterrupted medication supplies for more than a year.
2026 Goals
In 2026, Prixz aims to double sales compared with 2025, a target executives described as achievable given current demand trends and infrastructure capacity. Achieving this would position the company among the top one or two digital pharmacies in Mexico by revenue.
The company also plans to evolve from a digital pharmacy into a broader health technology platform by adding services beyond medication delivery. Planned offerings include diagnostic testing, health insurance products and physician appointment scheduling, integrating additional points of care into a unified digital ecosystem.
Meanwhile, Prixz is investing in artificial intelligence and adherence tools designed to increase treatment continuity. One initiative, Prixz Doctors, connects prescription issuance with fulfillment tracking, enabling physicians — subject to patient consent and privacy safeguards — to monitor refill behavior and medication adherence. Another tool, Claudia, is an AI-powered assistant currently in pilot testing. The system provides reminders and refill alerts for patients managing complex treatment schedules. Executives emphasized that the tool does not diagnose or prescribe but is intended to reduce missed doses and abandonment.
Prixz Plus, launched in January 2026 following pilot testing, functions as a loyalty and adherence program covering more than 2,000 products. The program offers discounts, treatment-based incentives and installment payment options, including for unbanked users. Management said the initiative is already used by thousands of patients and supported through partnerships with pharmaceutical laboratories.
© 2025 Mexicobusiness.News. A Mexico Business Company. All Rights Reserved.